Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, for the month of May 2022. The report discloses a corporate event announced via press release on May 5, 2022, regarding intellectual property developments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a specific event rather than a financial statement.
Material Changes
The material change disclosed is the issuance of two U.S. Patents (Nos. 11,304,976 and 11,318,163). These patents provide added intellectual property protection in the United States until at least 2036 for methods of treating sepsis using the Company's product, AllocetraTM.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the context of the patent issuance. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the scope and enforceability of U.S. Patent Nos. 11,304,976 and 11,318,163.
- Confirm the specific claims covering methods of treating sepsis with AllocetraTM.
- Review the full text of the press release furnished as Exhibit 99.1 for additional details.
- Check subsequent filings for any financial impact related to the patent maintenance or commercialization.